No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CMPS240816P7500
- 0.74
- -0.02-2.63%
15min DelayClose Jul 19 15:55 ET
0.74High0.74Low
0.74Open0.76Pre Close1 Volume608 Open Interest7.50Strike Price74.00Turnover82.80%IV7.40%PremiumAug 16, 2024Expiry Date0.20Intrinsic Value100Multiplier25DDays to Expiry0.54Extrinsic Value100Contract SizeAmericanOptions Type-0.4993Delta0.2487Gamma9.86Leverage Ratio-0.0120Theta-0.0027Rho-4.92Eff Leverage0.0078Vega
Intraday
- 5D
- Daily
News
Compass Pathways: Englebert's Appointment Effective July 8 >CMPS
Compass Pathways: Englebert's Appointment Effective July 8 >CMPS
Express News | Compass Pathways Appoints Lori Englebert as Chief Commercial Officer
Compass Pathways to Participate in Upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that
Express News | Cantor Fitzgerald Reiterates Overweight on Compass Pathways
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/21/2024 — Cantor Fitzgerald Reiterates → Overweight 05/13/2024 1791.73% HC Wainwright & Co. $120 → $12
Should You Buy the Dip on Compass Pathways Stock?
Comments
$COMPASS Pathways(CMPS.US$
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
$COMPASS Pathways(CMPS.US$
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.
Gainers:
• $Genco Shipping & Trading(GNK.US$ +4.7% (positive Barrons article)
• $NextDecade(NEXT.US$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways(CMPS.US$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo(GOEV.US$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg(AXL.US$ +3.7% (pr...
• $Genco Shipping & Trading(GNK.US$ +4.7% (positive Barrons article)
• $NextDecade(NEXT.US$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways(CMPS.US$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo(GOEV.US$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg(AXL.US$ +3.7% (pr...
21
Read more